The pharmaceutical and biotechnology industries will now have access to dedicated, focused scientific expertise in the drug development spectrum from discovery and preclinical through IND into Phase I research.
The acquisition is being structured as a merger, with Bio-Kinetic shareholders receiving membership interests in QPS Holdings. Private equity firms Argentum Capital Partners and First Analysis, which led the recapitalization of Bio-Kinetic in 2005, will become equity holders of QPS along with Bio-Kinetic’s two founders.
Dale Bourg, CEO of Bio-Kinetic, said: “The acquisition of Bio-Kinetic will provide our clients with access to industry experts in LC/MS/MS, ELISA, biomarkers and genotyping—complex procedures that can provide immense value in the decision-making process while developing a compound.”